Skip to main content
Erschienen in: Inflammopharmacology 2/2024

03.02.2024 | Original Article

Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines

verfasst von: Guojuan Sun, Guangzhi Wang, Heng Zhong

Erschienen in: Inflammopharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to evaluate the immunogenicity and safety of different types of poliovirus vaccines.

Methods

A randomized, blinded, single-center, parallel-controlled design was employed, and 360 infants aged ≥ 2 months were selected as study subjects. They were randomly assigned to bOPV group (oral Sabin vaccine) and sIPV group (Sabin strain inactivated polio vaccine), with 180 infants in each group. Adverse reaction events in the vaccinated subjects were recorded. The micro-neutralization test using cell culture was conducted to determine the geometric mean titer (GMT) of neutralizing antibodies against poliovirus types I, II, and III in different groups, and the seroconversion rates were calculated.

Results

Both groups exhibited a 100% seropositivity rate after booster immunization. The titers of neutralizing antibodies for the three types were predominantly distributed within the range of 1:128 to 1:512. The fold increase of type I antibodies differed markedly between the two groups (P < 0.05). Moreover, the fold increase of type II and type III antibodies for poliovirus differed slightly between the two groups (P > 0.05). The fourfold increase rate in sIPV group was drastically superior to that in bOPV group (P < 0.05). When comparing the post-immunization GMT levels of type I antibodies in individuals who completed the full course of spinal muscular atrophy vaccination, bOPV group showed greatly inferior levels to sIPV group (P < 0.05). For type II and type III antibodies, individuals in bOPV group demonstrated drastically superior post-immunization GMT levels to those in sIPV group (P < 0.05). The incidence of adverse reactions between the bOPV and sIPV groups differed slightly (P > 0.05).

Conclusion

These findings indicated that both the oral vaccine and inactivated vaccine had good safety and immunogenicity in infants aged ≥ 2 months. The sIPV group generated higher levels of neutralizing antibodies in serum, particularly evident in the post-immunization GMT levels for types II and III.
Literatur
Zurück zum Zitat Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, Sambou NA, Fofana S, Kanu FJ, Jeyaseelan V, Verma H, Weldon WC, Oberste MS, Sutter RW, Jeffries D, Wathuo M, Mach O, Clarke E (2022) Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. Lancet Glob Health 10:e257–e268PubMedCrossRef Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, Sambou NA, Fofana S, Kanu FJ, Jeyaseelan V, Verma H, Weldon WC, Oberste MS, Sutter RW, Jeffries D, Wathuo M, Mach O, Clarke E (2022) Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. Lancet Glob Health 10:e257–e268PubMedCrossRef
Zurück zum Zitat Bayliss J, Nissen M, Prakash D, Richmond P, Oh KB, Nolan T (2021) Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Hum Vaccin Immunother 17:176–190PubMedCrossRef Bayliss J, Nissen M, Prakash D, Richmond P, Oh KB, Nolan T (2021) Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Hum Vaccin Immunother 17:176–190PubMedCrossRef
Zurück zum Zitat Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora CFCB, Thierry-Carstensen B, Tingskov PN, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV (2020) Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: a phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine 38:530–538PubMedPubMedCentralCrossRef Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora CFCB, Thierry-Carstensen B, Tingskov PN, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV (2020) Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: a phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine 38:530–538PubMedPubMedCentralCrossRef
Zurück zum Zitat Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S (2020) Safety and immunogenicity of Vi-DT conjugate vaccine among 6–23-month-old children: phase II, randomized, dose-scheduling, observer-blind study. EClinicalMedicine 27:100540PubMedPubMedCentralCrossRef Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S (2020) Safety and immunogenicity of Vi-DT conjugate vaccine among 6–23-month-old children: phase II, randomized, dose-scheduling, observer-blind study. EClinicalMedicine 27:100540PubMedPubMedCentralCrossRef
Zurück zum Zitat Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, Han S, Wittawatmongkol O (2022) Safety and immunogenicity of a new inactivated polio vaccine made from sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis 226:308–318PubMedCrossRef Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, Han S, Wittawatmongkol O (2022) Safety and immunogenicity of a new inactivated polio vaccine made from sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis 226:308–318PubMedCrossRef
Zurück zum Zitat Chumakov K, Ehrenfeld E, Agol VI, Wimmer E (2021) Polio eradication at the crossroads. Lancet Glob Health 9:e1172–e1175PubMedCrossRef Chumakov K, Ehrenfeld E, Agol VI, Wimmer E (2021) Polio eradication at the crossroads. Lancet Glob Health 9:e1172–e1175PubMedCrossRef
Zurück zum Zitat Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Sáez-Llorens X (2020) Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: a randomized, observer-blind, controlled phase 1/2 trial. Vaccine 38:5313–5323PubMedPubMedCentralCrossRef Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Sáez-Llorens X (2020) Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: a randomized, observer-blind, controlled phase 1/2 trial. Vaccine 38:5313–5323PubMedPubMedCentralCrossRef
Zurück zum Zitat Dakin A, Borrow R, Arkwright PD (2023) A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients. Expert Rev Vaccines 22:104–117PubMedCrossRef Dakin A, Borrow R, Arkwright PD (2023) A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients. Expert Rev Vaccines 22:104–117PubMedCrossRef
Zurück zum Zitat De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P (2021) Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 397:39–50PubMedPubMedCentralCrossRef De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P (2021) Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 397:39–50PubMedPubMedCentralCrossRef
Zurück zum Zitat Leo DE, Cappelli V, Massaro MG, Tosti C, Morgante G (2017) Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women. Minerva Ginecol 69:336–341PubMed Leo DE, Cappelli V, Massaro MG, Tosti C, Morgante G (2017) Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women. Minerva Ginecol 69:336–341PubMed
Zurück zum Zitat Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, Perminova O, Kobashi IAR, Bae CW, Ojeda J, Park J, Chansinghakul D, B’Chir S, Neveu D, Bonaparte M, Jordanov E (2021) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect 149:e90PubMedPubMedCentralCrossRef Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, Perminova O, Kobashi IAR, Bae CW, Ojeda J, Park J, Chansinghakul D, B’Chir S, Neveu D, Bonaparte M, Jordanov E (2021) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect 149:e90PubMedPubMedCentralCrossRef
Zurück zum Zitat Duintjer Tebbens RJ, Thompson KM (2018) Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 17:739–751PubMedPubMedCentralCrossRef Duintjer Tebbens RJ, Thompson KM (2018) Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 17:739–751PubMedPubMedCentralCrossRef
Zurück zum Zitat Fadlyana E, Dhamayanti M, Tarigan R, Mulia Sari R, Sjafri Bachtiar N, Kartasasmita CB, Rusmil K (2020) Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Vaccine 38:1962–1967PubMedCrossRef Fadlyana E, Dhamayanti M, Tarigan R, Mulia Sari R, Sjafri Bachtiar N, Kartasasmita CB, Rusmil K (2020) Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Vaccine 38:1962–1967PubMedCrossRef
Zurück zum Zitat Falleiros-Arlant LH, Ayala SEG, Domingues C, Brea J, Colsa-Ranero A (2020) Current status of poliomyelitis in Latin America. Rev Chilena Infectol 37:701–709PubMedCrossRef Falleiros-Arlant LH, Ayala SEG, Domingues C, Brea J, Colsa-Ranero A (2020) Current status of poliomyelitis in Latin America. Rev Chilena Infectol 37:701–709PubMedCrossRef
Zurück zum Zitat Feng G, Jiang D, Han W, Xie Z, Jiang Z, Huang L, Wang J, Zhang W, Xu L, Tan J, You W, Cui G, Li C, Wang Y (2023) Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. Int J Infect Dis 130:20–27PubMedCrossRef Feng G, Jiang D, Han W, Xie Z, Jiang Z, Huang L, Wang J, Zhang W, Xu L, Tan J, You W, Cui G, Li C, Wang Y (2023) Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. Int J Infect Dis 130:20–27PubMedCrossRef
Zurück zum Zitat Ferlito C, Visco V, Biselli R, Cattaruzza MS, Carreras G, Salerno G, Lista F, Capobianchi MR, Castilletti C, Lapa D, Antonelli G, Gentile M, Sorice M, Riitano G, Lucania G, Riccieri V, Mainiero F, Angeloni A, Lucarelli M, Ferraguti G, Autore A, Lastilla M, Salemi S, Biondo MI, Picchianti-Diamanti A, Caporuscio S, Teloni R, Mariotti S, Nisini R, D’Amelio R (2021) Safety of multiple vaccinations and durability of vaccine-induced antibodies in an Italian military cohort 5 years after immunization. Biomedicines 10:6PubMedPubMedCentralCrossRef Ferlito C, Visco V, Biselli R, Cattaruzza MS, Carreras G, Salerno G, Lista F, Capobianchi MR, Castilletti C, Lapa D, Antonelli G, Gentile M, Sorice M, Riitano G, Lucania G, Riccieri V, Mainiero F, Angeloni A, Lucarelli M, Ferraguti G, Autore A, Lastilla M, Salemi S, Biondo MI, Picchianti-Diamanti A, Caporuscio S, Teloni R, Mariotti S, Nisini R, D’Amelio R (2021) Safety of multiple vaccinations and durability of vaccine-induced antibodies in an Italian military cohort 5 years after immunization. Biomedicines 10:6PubMedPubMedCentralCrossRef
Zurück zum Zitat Fukushima S, Nakano T, Shimizu H, Hamada A (2022) Immunogenicity of catch-up immunization with conventional inactivated polio vaccine among Japanese adults. Vaccines (basel) 10:2160PubMedCrossRef Fukushima S, Nakano T, Shimizu H, Hamada A (2022) Immunogenicity of catch-up immunization with conventional inactivated polio vaccine among Japanese adults. Vaccines (basel) 10:2160PubMedCrossRef
Zurück zum Zitat Gao S, Wei M, Chu K, Li J, Zhu F (2022) Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Hum Vaccin Immunother 18:2050106PubMedPubMedCentralCrossRef Gao S, Wei M, Chu K, Li J, Zhu F (2022) Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Hum Vaccin Immunother 18:2050106PubMedPubMedCentralCrossRef
Zurück zum Zitat GBD (2020) Release 1, vaccine coverage collaborators (2021) measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the global burden of disease study 2020, release 1. Lancet 398:503–521 GBD (2020) Release 1, vaccine coverage collaborators (2021) measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the global burden of disease study 2020, release 1. Lancet 398:503–521
Zurück zum Zitat Jaiswal N, Singh S, Agarwal A, Chauhan A, Thumburu KK, Kaur H, Singh M (2019) Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database Syst Rev 12:CD011780PubMed Jaiswal N, Singh S, Agarwal A, Chauhan A, Thumburu KK, Kaur H, Singh M (2019) Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database Syst Rev 12:CD011780PubMed
Zurück zum Zitat Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M (2021) Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 39:1463–1471PubMedCrossRef Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M (2021) Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 39:1463–1471PubMedCrossRef
Zurück zum Zitat Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, Fall G, Dia M, Bob NS, Monath TP, Barrett AD, Hombach J, Mulogo EM, Ampeire I, Karanja HK, Nyehangane D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF (2021) Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 397:119–127PubMedPubMedCentralCrossRef Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, Fall G, Dia M, Bob NS, Monath TP, Barrett AD, Hombach J, Mulogo EM, Ampeire I, Karanja HK, Nyehangane D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF (2021) Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 397:119–127PubMedPubMedCentralCrossRef
Zurück zum Zitat Li Z, Xu J, Tan H, Zhang C, Chen J, Ni L, Yun X, Huang Y, Wang W (2020) Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis 99:149–155PubMedCrossRef Li Z, Xu J, Tan H, Zhang C, Chen J, Ni L, Yun X, Huang Y, Wang W (2020) Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis 99:149–155PubMedCrossRef
Zurück zum Zitat Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, Yang J, Yin Z, Wang J, Chu J, Cai W, Zhou J, Wang J, Li Q (2016) Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine. J Infect Dis 214:1728–1734PubMedCrossRef Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, Yang J, Yin Z, Wang J, Chu J, Cai W, Zhou J, Wang J, Li Q (2016) Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine. J Infect Dis 214:1728–1734PubMedCrossRef
Zurück zum Zitat Liu B, Cao B, Wang C, Han B, Sun T, Miao Y, Lu Q, Cui F (2022) Immunogenicity and safety of childhood combination vaccines: a systematic review and meta-analysis. Vaccines (basel) 10:472PubMedCrossRef Liu B, Cao B, Wang C, Han B, Sun T, Miao Y, Lu Q, Cui F (2022) Immunogenicity and safety of childhood combination vaccines: a systematic review and meta-analysis. Vaccines (basel) 10:472PubMedCrossRef
Zurück zum Zitat Lohiniva AL, Nurzhynska A, Alhassan H, Shetye M, Ayiku P (2022) Understanding factors influencing polio vaccine uptake in Ghana-developing meaningful community mobilization and engagement strategies in collaboration with religious leaders. Am J Trop Med Hyg 107:1345–1350PubMedPubMedCentralCrossRef Lohiniva AL, Nurzhynska A, Alhassan H, Shetye M, Ayiku P (2022) Understanding factors influencing polio vaccine uptake in Ghana-developing meaningful community mobilization and engagement strategies in collaboration with religious leaders. Am J Trop Med Hyg 107:1345–1350PubMedPubMedCentralCrossRef
Zurück zum Zitat Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F (2022) Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India. Vaccine X 11:100190PubMedPubMedCentralCrossRef Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F (2022) Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India. Vaccine X 11:100190PubMedPubMedCentralCrossRef
Zurück zum Zitat Mansoor I, Eassa HA, Mohammed KHA, Abd El-Fattah MA, Abdo MH, Rashad E, Eassa HA, Saleh A, Amin OM, Nounou MI, Ghoneim O (2022) Microneedle-based vaccine delivery: review of an emerging technology. AAPS PharmSciTech 23:103PubMedCrossRef Mansoor I, Eassa HA, Mohammed KHA, Abd El-Fattah MA, Abdo MH, Rashad E, Eassa HA, Saleh A, Amin OM, Nounou MI, Ghoneim O (2022) Microneedle-based vaccine delivery: review of an emerging technology. AAPS PharmSciTech 23:103PubMedCrossRef
Zurück zum Zitat Modlin JF, Bandyopadhyay AS, Sutter R (2021) Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication. J Infect Dis 224:S398–S404PubMedPubMedCentralCrossRef Modlin JF, Bandyopadhyay AS, Sutter R (2021) Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication. J Infect Dis 224:S398–S404PubMedPubMedCentralCrossRef
Zurück zum Zitat Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H (2020) Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. J Infect Chemother 26:651–659PubMedCrossRef Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H (2020) Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. J Infect Chemother 26:651–659PubMedCrossRef
Zurück zum Zitat Qiu X, Chen K, Tong L, Shu X, Lü X, Wen H, Deng C (2004) Effects of moxibustion at shenque (CV 8) on serum IL-12 level and NK cell activities in mice with transplanted tumor. J Tradit Chin Med 24:56–58PubMed Qiu X, Chen K, Tong L, Shu X, Lü X, Wen H, Deng C (2004) Effects of moxibustion at shenque (CV 8) on serum IL-12 level and NK cell activities in mice with transplanted tumor. J Tradit Chin Med 24:56–58PubMed
Zurück zum Zitat Sáez-Llorens X, Chan M, DeAntonio R, Petersen T, Olesen C, Jensen JS, Sørensen C, Ekstrand LM, Czort MK, Kristensen HH, Thulstrup N, Christoffersen DB (2022) Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. Vaccine 40:5835–5841PubMedPubMedCentralCrossRef Sáez-Llorens X, Chan M, DeAntonio R, Petersen T, Olesen C, Jensen JS, Sørensen C, Ekstrand LM, Czort MK, Kristensen HH, Thulstrup N, Christoffersen DB (2022) Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. Vaccine 40:5835–5841PubMedPubMedCentralCrossRef
Zurück zum Zitat Sharma H, Lalwani S, Parekh S, Pujari P, Shewale S, Palkar S, Hanumante N, Gokhale S, Ks J, Kumar R, Sharma I, Gairola S (2022) A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months. Hum Vaccin Immunother 18:2146435PubMedPubMedCentralCrossRef Sharma H, Lalwani S, Parekh S, Pujari P, Shewale S, Palkar S, Hanumante N, Gokhale S, Ks J, Kumar R, Sharma I, Gairola S (2022) A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months. Hum Vaccin Immunother 18:2146435PubMedPubMedCentralCrossRef
Zurück zum Zitat Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Bougouma EC, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Oshinsky JJ, Pasetti MF, Neuzil KM, Laurens MB (2021a) Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis 108:465–472PubMedPubMedCentralCrossRef Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Bougouma EC, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Oshinsky JJ, Pasetti MF, Neuzil KM, Laurens MB (2021a) Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis 108:465–472PubMedPubMedCentralCrossRef
Zurück zum Zitat Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MB (2021b) Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. Int J Infect Dis 102:517–523PubMedPubMedCentralCrossRef Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MB (2021b) Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. Int J Infect Dis 102:517–523PubMedPubMedCentralCrossRef
Zurück zum Zitat Sultan MA (2022) Emerging challenges to realizing global polio eradication and their solutions. East Mediterr Health J 28:515–520CrossRef Sultan MA (2022) Emerging challenges to realizing global polio eradication and their solutions. East Mediterr Health J 28:515–520CrossRef
Zurück zum Zitat Sun X, Xu Y, Tang F, Xiao Y, Wang Z, Wang B, Zhu X, Yang X, Chen H (2022) Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: a multicenter, randomized, non-inferiority, controlled trial. Front Immunol 13:905634PubMedPubMedCentralCrossRef Sun X, Xu Y, Tang F, Xiao Y, Wang Z, Wang B, Zhu X, Yang X, Chen H (2022) Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: a multicenter, randomized, non-inferiority, controlled trial. Front Immunol 13:905634PubMedPubMedCentralCrossRef
Zurück zum Zitat Syed YY (2019) DTaP-IPV-HepB-Hib vaccine (Hexyon®): an updated review of its use in primary and booster vaccination. Paediatr Drugs 21:397–408PubMedPubMedCentralCrossRef Syed YY (2019) DTaP-IPV-HepB-Hib vaccine (Hexyon®): an updated review of its use in primary and booster vaccination. Paediatr Drugs 21:397–408PubMedPubMedCentralCrossRef
Zurück zum Zitat Thompson KM, Kalkowska DA (2021) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 41:229–247PubMedCrossRef Thompson KM, Kalkowska DA (2021) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 41:229–247PubMedCrossRef
Zurück zum Zitat Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P (2018) Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr 172:1045–1052PubMedPubMedCentralCrossRef Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P (2018) Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr 172:1045–1052PubMedPubMedCentralCrossRef
Zurück zum Zitat Yang K, Kim H, Ortiz E, Huoi C, Kang J (2023) Post-marketing safety surveillance of a childhood pentavalent diphtheria-tetanus-acellular pertussis-polio and haemophilus influenzae type B (DTaP-IPV//Hib) vaccine in South Korea. Infect Dis Ther 12:499–511PubMedCrossRef Yang K, Kim H, Ortiz E, Huoi C, Kang J (2023) Post-marketing safety surveillance of a childhood pentavalent diphtheria-tetanus-acellular pertussis-polio and haemophilus influenzae type B (DTaP-IPV//Hib) vaccine in South Korea. Infect Dis Ther 12:499–511PubMedCrossRef
Zurück zum Zitat Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, Mainou BA, Konopka-Anstadt JL, Hendley WS, Vincent A, Clemens R, Clemens SAC, Ross AG, Clemens JD, Tritama E (2023) Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet 401:131–139PubMedPubMedCentralCrossRef Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, Mainou BA, Konopka-Anstadt JL, Hendley WS, Vincent A, Clemens R, Clemens SAC, Ross AG, Clemens JD, Tritama E (2023) Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet 401:131–139PubMedPubMedCentralCrossRef
Zurück zum Zitat Zhang Y, Guo Y, Dong Y, Liu Y, Zhao Y, Yu S, Li S, Wu C, Yang B, Li W, Wei X, Zhang Y, Huang Y, Wang H, Yang X (2022) Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models. Hum Vaccin Immunother 18:2160158PubMedPubMedCentralCrossRef Zhang Y, Guo Y, Dong Y, Liu Y, Zhao Y, Yu S, Li S, Wu C, Yang B, Li W, Wei X, Zhang Y, Huang Y, Wang H, Yang X (2022) Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models. Hum Vaccin Immunother 18:2160158PubMedPubMedCentralCrossRef
Zurück zum Zitat Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, Ye H, Zhao Z, Liu X, Li J, Li Y, Li R, Jiang R, Wang J, Fu Y, Ma R, Shi H, Yang H, Li C, Yang J, Li Q (2021) Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med 9:253PubMedPubMedCentralCrossRef Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, Ye H, Zhao Z, Liu X, Li J, Li Y, Li R, Jiang R, Wang J, Fu Y, Ma R, Shi H, Yang H, Li C, Yang J, Li Q (2021) Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med 9:253PubMedPubMedCentralCrossRef
Zurück zum Zitat Zheng Y, Ying Z, Zou Y, Zhu T, Qian D, Han W, Jiang Y, Jiang Z, Li X, Wang J, Lei J, Xu L, Jiang D, Li C, Liu X (2022) Safety, immunogenicity and lot-to-lot consistency of sabin-strain inactivated poliovirus vaccine in 2-month-old infants: a double-blind. Randomized phase III trial. Vaccines (basel) 10:254PubMedCrossRef Zheng Y, Ying Z, Zou Y, Zhu T, Qian D, Han W, Jiang Y, Jiang Z, Li X, Wang J, Lei J, Xu L, Jiang D, Li C, Liu X (2022) Safety, immunogenicity and lot-to-lot consistency of sabin-strain inactivated poliovirus vaccine in 2-month-old infants: a double-blind. Randomized phase III trial. Vaccines (basel) 10:254PubMedCrossRef
Metadaten
Titel
Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines
verfasst von
Guojuan Sun
Guangzhi Wang
Heng Zhong
Publikationsdatum
03.02.2024
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 2/2024
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01395-7

Weitere Artikel der Ausgabe 2/2024

Inflammopharmacology 2/2024 Zur Ausgabe